Alexion And Synageva BioPharma Announce Early Termination Of Hart-Scott-Rodino Waiting Period For Alexion’s Pending Acquisition Of Synageva

CHESHIRE, Conn. & LEXINGTON, Mass.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Alexion’s pending acquisition of Synageva. The waiting period was scheduled to expire on June 15, 2015.

Help employers find you! Check out all the jobs and post your resume.